Fig 5.

Estimated relative risk and absolute risk reduction of the composite outcome of admission to hospital or death across various population groups. Effect of nirmatrelvir compared with no treatment group in those aged ≤65 years and > 65 years; in men and women; in black and white participants; in those with 1-2, 3-4 risk, and ≥5 risk factors for progression to severe covid-19 illness; and in those infected during the omicron BA.1 or BA.2 predominant era, and BA.5 predominant era. CI=confidence interval